marijuana epidiolex_00031616.jpg
marijuana epidiolex_00031616.jpg
Now playing
04:53
Turning point for marijuana as medicine?
KVVU
Now playing
00:59
Pot yoga: Highly relaxing and then some
Jonathan Reyes/CNN
Now playing
01:39
Your brain on marijuana
CNN
Now playing
01:22
The dangers of synthetic marijuana
An Israeli agricultural engineer inspects marijuana plants at the BOL (Breath Of Life) Pharma greenhouse in the country's second-largest medical cannabis plantation, near Kfar Pines in northern Israel, on March 9, 2016.
The recreational use of cannabis is illegal in the Jewish state, but for the past 10 years its therapeutic use has not only been permitted but also encouraged. Last year, doctors prescribed the herb to about 25,000 patients suffering from cancer, epilepsy, post-traumatic stress and degenerative diseases. The purpose is not to cure them but to alleviate their symptoms. Forbidden to export its cannabis plants, Israel is concentrating instead on marketing its agronomic, medical and technological expertise in the hope of becoming a world hub in the field.
 / AFP / JACK GUEZ        (Photo credit should read JACK GUEZ/AFP/Getty Images)
JACK GUEZ/AFP/Getty Images
An Israeli agricultural engineer inspects marijuana plants at the BOL (Breath Of Life) Pharma greenhouse in the country's second-largest medical cannabis plantation, near Kfar Pines in northern Israel, on March 9, 2016. The recreational use of cannabis is illegal in the Jewish state, but for the past 10 years its therapeutic use has not only been permitted but also encouraged. Last year, doctors prescribed the herb to about 25,000 patients suffering from cancer, epilepsy, post-traumatic stress and degenerative diseases. The purpose is not to cure them but to alleviate their symptoms. Forbidden to export its cannabis plants, Israel is concentrating instead on marketing its agronomic, medical and technological expertise in the hope of becoming a world hub in the field. / AFP / JACK GUEZ (Photo credit should read JACK GUEZ/AFP/Getty Images)
Now playing
02:28
Why weed is stuck in a legal limbo
John Lustig and his wife Anne learn about cannabis lotions
Jen Christensen, CNN
John Lustig and his wife Anne learn about cannabis lotions
Now playing
02:36
Seniors get on board the Cannabus
 GO WITH AFP STORY by Desiree Martin A picture taken on April 12, 2013 shows plants of marijuana at the plantation of the Sibaratas Med Can association in Mogan on the southwest coast of the island of Gran Canaria. The plants grow from cuttings for approximately two months and then blossom before being harvested, dried, stored in jars for a month and later processed to be consumed on site. Spanish law prohibits the possession of soft drugs like cannabis in public and its growth to be sold for profit is illegal. But the law does tolerate growing cannabis for personal use and its consumption in private. Dozens of private marijuana smoking clubs operate across Spain that take advantage of this legal loophole that serve cannabis users who do not want to get their drugs from the streets. AFP PHOTO / DESIREE MARTIN (Photo credit should read DESIREE MARTIN/AFP/Getty Images)
DESIREE MARTIN/AFP/Getty Images
GO WITH AFP STORY by Desiree Martin A picture taken on April 12, 2013 shows plants of marijuana at the plantation of the Sibaratas Med Can association in Mogan on the southwest coast of the island of Gran Canaria. The plants grow from cuttings for approximately two months and then blossom before being harvested, dried, stored in jars for a month and later processed to be consumed on site. Spanish law prohibits the possession of soft drugs like cannabis in public and its growth to be sold for profit is illegal. But the law does tolerate growing cannabis for personal use and its consumption in private. Dozens of private marijuana smoking clubs operate across Spain that take advantage of this legal loophole that serve cannabis users who do not want to get their drugs from the streets. AFP PHOTO / DESIREE MARTIN (Photo credit should read DESIREE MARTIN/AFP/Getty Images)
Now playing
02:11
Will recreational marijuana soon be legal nationwide?
CNN
Now playing
02:35
The weed distributor fighting 'big marijuana'
nfl marijuana use goodell fitzgerald bts_00001009.jpg
NFL Network
nfl marijuana use goodell fitzgerald bts_00001009.jpg
Now playing
00:48
Goodell addresses NFL ban on marijuana use
CNN Illustration/Getty Images
Now playing
02:00
California pushing back on Sessions' pot memo
AG Sessions, Rosenstein, Gore Civil Rights Ceremony
CNN
AG Sessions, Rosenstein, Gore Civil Rights Ceremony
Now playing
01:47
Sessions to rescind Obama-era marijuana policy
Jeff Sessions NAAG remarks medical marijuana_00004720.jpg
CNN
Jeff Sessions NAAG remarks medical marijuana_00004720.jpg
Now playing
01:12
Sessions: Marijuana won't fix opioid epidemic
california weed vs whiskey sidner pkg _00001109.jpg
CNN
california weed vs whiskey sidner pkg _00001109.jpg
Now playing
04:07
Will weed be bigger than whiskey?
CNN
Now playing
02:24
Designer marijuana boost THC potency
marijuana edibles high profits_00000130.jpg
marijuana edibles high profits_00000130.jpg
Now playing
01:09
Is eating marijuana riskier than smoking it?
history medical marijuana orig nws_00003424.jpg
history medical marijuana orig nws_00003424.jpg
Now playing
01:56
The quick hit history of medical marijuana
(CNN) —  

Epidiolex, the first cannabis-based medication approved by the US Food and Drug Administration, is now available by prescription in all 50 states.

The twice-daily oral solution is approved for use in patients 2 and older to treat two types of epileptic syndromes: Dravet syndrome, a rare genetic dysfunction of the brain that begins in the first year of life, and Lennox-Gastaut syndrome, a form of epilepsy with multiple types of seizures that begins in early childhood, usually between ages 3 and 5.

“Because these patients have historically not responded well to available seizure medications, there has been a dire need for new therapies that aim to reduce the frequency and impact of seizures,” said Justin Gover, CEO of GW Pharmaceuticals, the maker of Epidiolex, in a written statement. “We are committed to ensuring that these patients can access this novel cannabinoid medicine that has been thoroughly studied in clinical trials, manufactured to assure quality and consistency, and is eligible to be covered by insurance for appropriate patients.”

Epidiolex was recommended for approval by an advisory committee in April and approved by the FDA in June. In September, the US Department of Justice and the Drug Enforcement Administration classified Epidiolex as a Schedule V substance, clearing the final hurdle for it to be legally prescribed by doctors in the United States. (Marijuana and CBD remain Schedule I substances.)

“Adequate and well-controlled clinical studies supported Epidiolex’s approval, so prescribers can have confidence in the drug’s uniform strength and consistent delivery that support appropriate dosing needed for treating patients with these complex and serious epilepsy syndromes,” FDA Commissioner Dr. Scott Gottlieb said in a written statement. “The FDA will continue to support rigorous scientific research on the potential medical uses of marijuana-derived products and stand ready to work with product developers who are interested in bringing patients safe and effective, high quality products.”

Dr. Orrin Devinsky, director of the Comprehensive Epilepsy Center at NYU Langone Health, served as the lead investigator of two of three phase three clinical trials of Epidiolex.

“In those syndromes, when [Epidiolex] was added to three other seizure [medications], on average, it reduced convulsive seizures – or ‘drop seizures’ – by about 25% to 28% compared to a placebo,” Devinsky said. “So I think it’s very important to recognize … that it clearly is effective, and this was statistically significant in all three of the large studies that we did, but by the same token, the effect was modest.

“There are some people who had dramatic improvements. Many had a modest improvement, and some had no improvement. So it’s not a miracle drug. It’s an effective drug, and I think its side effect profile is quite good compared to other seizure drugs that we have, but it’s not a miracle cure,” Devinsky said.

The most common side effects of Epidiolex, according to GW Pharmaceuticals, include sleepiness, decreased appetite, diarrhea and an increase in liver enzymes.

Shauna Garris, a pharmacist, pharmacy clinical specialist and adjunct assistant professor at the University of North Carolina’s Eshelman School of Pharmacy, said the drug is effective and works somewhere between “fairly” and “very well.” She has not used Epidiolex in her own clinical practice and was not involved in the development of the drug but said she’s not sure it will live up to “all of the hype” that has surrounded it.

Still, she said the FDA’s approval of Epidiolex signals “validation of the science of cannabinoid medication.”

GW Pharmaceuticals says the average list price of Epidiolex is $32,500 a year. The company expects that the drug will be covered by most insurance plans and asserts that “this price is in line with other branded, FDA-approved anti-epileptic drugs (AEDs), such as Banzel, and access for eligible patients is expected to be similar to such AEDs for similar indications for LGS (e.g., Onfi and Banzel).”

It is also launching a patient support program “to help patients who have been prescribed Epidiolex gain access to therapy. The program offers patient/caregiver-focused education and resources to help lower out-of-pocket costs or provide product at no cost for eligible patients.”

Although Epidiolex is approved only for the treatment of two rare seizure disorders, doctors can now prescribe the medication “off-label” for other conditions. According to the US Department of Health and Human Services, this is both legal and common; one in five of all medications prescribed is for off-label use.

Get CNN Health's weekly newsletter

Sign up here to get The Results Are In with Dr. Sanjay Gupta every Tuesday from the CNN Health team.

“The off-label use of CBD and Epidiolex will be a fascinating subject to look at over the coming years,” Devinsky said. “Many, many patients would like to have access to it who don’t fit the criteria, and I believe many doctors will try to prescribe it, as will I for some people who I think have tried many, many medications and for whom it might be beneficial.”

He added, “I think doctors are always trying to make those decisions about a good benefit-to-toxicity ratio, and CBD is a fairly attractive compound. The question is, what will the insurance companies do?”

CNN’s Susan Scutti contributed to this report.